Compare Inovio Pharmaceuticals Inc (INO) vs ProShares UltraPro Short QQQ ETF (SQQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs ProShares UltraPro Short QQQ ETF — how do they compare? Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M), while ProShares UltraPro Short QQQ ETF trades at $32.95 (market cap $2.23B). The key difference: ProShares UltraPro Short QQQ ETF is far larger — about 19.9× Inovio Pharmaceuticals Inc's market cap, and Inovio Pharmaceuticals Inc is trading nearer its 52-week high, ProShares UltraPro Short QQQ ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and ProShares UltraPro Short QQQ ETF for 12 Days on average.
| INO | SQQQ | |
|---|---|---|
Market Cap | $112.19M | $2.23B |
Volume | 3,201,278 | 60,436,012 |
Sector | Health | Leveraged / Inverse |
52-Week High | $2.65 | $89.43 |
52-Week Low | $0.66 | $31.83 |
Typical Hold Time | 43 Days | 12 Days |
Enterprise Value | $83.51M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO Pharmaceuticals trades at $1.09, down 5.63% today, with a bearish technical outlook despite positive analyst sentiment. The company faces significant fundamental challenges with minimal revenue of $65,340 in 2025 and substantial losses of $84.95 million. Key catalyst is the October 30, 2026 FDA decision on INO-3107 for recurrent respiratory papillomatosis, which could transform the company's prospects if approved.
Investment outlook hinges on FDA approval of INO-3107, with analysts maintaining a $2.75 consensus target representing 152% upside. However, persistent cash burn and negative profitability metrics pose substantial risks. The stock offers high-risk, high-reward potential for investors comfortable with binary regulatory outcomes in biotech.
SQQQ trades at $32.95, up 2.71% with a bearish technical signal from moving averages while oscillators remain neutral. The ETF shows no traditional financial ratios as it's an inverse leveraged product designed to move opposite the Nasdaq 100. Recent news highlights its role as a hedging tool against tech sector declines, with articles discussing strategic pairing with QQQ positions.
As a 3x leveraged inverse ETF, SQQQ carries significant risk from daily rebalancing and decay. It serves as a tactical tool for bearish Nasdaq 100 views or portfolio hedging, but requires active management. The primary risk remains volatility decay and timing sensitivity in a market where tech stocks have shown long-term growth trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About ProShares UltraPro Short QQQ ETF
SQQQ is a leveraged inverse ETF that seeks daily investment results, before fees and expenses, that correspond to three times the inverse (-3x) of the daily performance of the Nasdaq-100 Index. It is a tactical trading tool designed for sophisticated investors to profit from or hedge against declines in large-cap technology and growth stocks. Due to its daily reset and the effects of compounding, it is intended for short-term use and carries significant risk if held during periods of high market volatility.
Read more on SQQQ →
